Please provide your email address to receive an email when new articles are posted on . Lymphopenia at diagnosis or during follow-up can predict OS among patients with multiple myeloma. Researchers ...
A mathematical model using pharmacodynamic parameters, including duration of hyperlymphocytosis, may help clinicians better predict patient responses to ibrutinib administered for chronic lymphocytic ...
Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum Data for 239 patients, ...
Impact of venous thromboembolism on survival in multiple myeloma patients receiving bispecific antibody therapy: Insights from real-world data. Risk of second primary hematological malignancy post CAR ...
Measuring the lymphocytes — white blood cells that fight infection — in a patient’s blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to ...
(A) Principal component analysis (PCA) of lymphocyte subsets and factors such as age in Control, LC, and LC-PTB groups, and the joint analysis of LC & LC-PTB. PC1 and PC2 represent the first and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results